CLX — The Clorox Company

The tape is clearly negative: as of 2026-09-13 the shares were down 17.0% in one month, 20.7% over six months, and ~11.6% below the 50-day SMA, hugging the 52-week low. The August 3, 2026 Q4/FY26 print showed net sales of $1.95B (-2% YoY) with adjusted EPS of $1.66 collapsing 42% YoY (vs. $2.87) on weaker organic volumes, GOJO inventory step-up costs and heavier advertising. Analysts responded by cutting targets (Wells Fargo $102→$90 Equal Weight; UBS Neutral, $105) and the rating distribution is 20 Hold / 6 Sell / 3 Buy — no strong buys. Add a CEO succession search for Linda Rendle and there's no near-term narrative to lean against the selling.

The three-year trend is decelerating, not inflecting upward. Total revenue was roughly flat FY24→FY25 (~$7.09B→$7.10B) before falling to ~$6.72B in FY26 (-5.4%), and even Q4 FY26 revenue of $1.948B was -2% YoY despite GOJO adding a meaningful top-line contribution — implying the underlying base business contracted. Margins are compressing: Q4 FY26 gross margin fell 520 bps YoY to 41.3%, and GAAP diluted EPS by quarter ($0.65 → $1.29 → $1.54 → $1.33 across FY26 vs. $0.79 → $1.54 → $1.50 → $2.68 in FY25) shows a clear year-over-year step down. Free cash flow fell to ~$405M in FY26 from ~$761M in FY25, with a -$165M outflow in the March 2026 quarter. This looks like a genuine slump with a large, identifiable one-off layer (GOJO step-up costs) on top — a recent blip and a real trend tangled together, which is exactly why the Nov 3, 2026 Q1 FY27 print is the pivotal read.

Cheap-with-caveats as of 2026-09-13. TTM P/E is 18.2x, but the forward P/E is only ~15.2x ($87.76 ÷ $5.79 FY27E EPS) versus a ~$100 consensus target and a ~53x distorted 5-year average P/E (dragged by depressed-earnings years). P/S is 1.58x versus a 5-year average of 2.25x, and the trailing dividend yield of 4.70% rises to ~5.7% on the newly raised $1.25/quarter payout. The catch: P/B of ~119x is meaningless because equity has been eroded to ~$90M, ROE of 6.5% flatters nothing, and the ~3.8% FCF yield (FY26 FCF of $405M) is thin. So the stock is genuinely cheap versus its own history on earnings and sales, but the discount tracks real leverage, growth and execution problems rather than a mispricing alone.

The market is pricing in the mess, not the fix. At ~15x forward earnings the shares already discount soft volumes, integration costs, and a cautious +0-1% organic guide — so an in-line FY27 that merely laps the GOJO step-up costs (street models $5.79 EPS, +20% vs $4.82 TTM) would likely re-rate the multiple. The flip side: if underlying volumes stay negative and FCF cannot cover the ~$5.00/share dividend, the 'cheap' 15x could stay cheap or compress further. This is a pay-for-the-turnaround setup — asymmetric, but you are buying a recovery that has not yet shown up in the numbers.

Deeply oversold and in a confirmed downtrend as of 2026-09-13: RSI(14) 23.0, price 11.9% below the 20-day SMA, 11.6% below the 50-day, and 14.75% below the 200-day, with $87.76 barely above the $84.70 52-week low. Oversold readings can produce sharp bounces, but there is no base or positive momentum divergence yet — the trend is still down and every moving average is overhead resistance. Entry-timing implication: don't try to catch the falling knife; wait for the price to reclaim the 20-day SMA and/or for RSI to turn back above 30 with the Nov 3 earnings in hand.

• Input-cost and supply-chain inflation — Q4 FY26 gross margin contracted 520 bps YoY to 41.3% on raw-material, labor and logistics costs, with step-up and integration costs layered on top.
• Soft, cost-conscious consumer — lighter volume/takeaway trends across staples are capping pricing power and holding management's organic growth guide to just +0% to +1%.
• Interest rates and leverage — long-term debt jumped to $3.98B (from $2.49B) post-GOJO against a current ratio of 0.66 and $143M of cash, making CLX more rate-sensitive than a typical staples name.
• Defensive-sector rotation — staples have lagged as capital chased growth; a ~4.7% trailing (higher forward) yield makes CLX a candidate for income rotation if rates ease.
• Private-label and channel competition — value trade-down plus e-commerce/mass/club channel shifts pressure share in cleaning and household categories.

• Q1 FY27 earnings, expected Nov 3, 2026 — first clean read on organic growth stabilization, Purell/GOJO demand and gross-margin recovery.
• Announcement of a successor to Chair/CEO Linda Rendle — could re-focus strategy or add risk depending on the pick.
• Realization of the simplified operating structure announced June 2026 and GOJO synergies, plus the lapping of one-off step-up costs that could swing FY27 EPS sharply higher.
• Dividend/capital-return updates — the July 2026 hike to $1.25/quarter sustains a multi-decade streak, but coverage is the question.

• Organic volume weakness persists — reported FY26 revenue fell ~5.4% and Q4 ~2% YoY despite GOJO's contribution, signaling soft underlying demand.
• Dividend may not be covered — FY26 FCF of ~$405M versus roughly $600M of dividends paid; a sustained shortfall would pressure the payout or force more debt.
• Leveraged, thin-equity balance sheet — $3.98B long-term debt, current ratio 0.66, equity of just $90M; little cushion if earnings miss.
• GOJO integration and CEO transition create execution and key-person risk exactly when stability is needed.
• Value-trap risk — shares are deeply oversold near a 52-week low, but oversold names keep falling if the Nov 3 guide disappoints.

Clorox is a genuine blue-chip staples franchise (20.4% ROIC, ~50-year dividend streak, 4.7%+ yield) trading at a real discount (~15x forward earnings vs. a low-to-mid $90s fair value estimate), but the FY26 numbers are deteriorating, FCF no longer covers the dividend, debt has ballooned with GOJO, and the CEO is leaving. This is a 'show-me' turnaround, not a buy on the numbers today — the April 2026 GOJO deal and the November 3 print are the swing factors, and until volumes and margins stabilize the cheap multiple is as likely to be a value trap as an opportunity.

Primary method: justified forward P/E on FY27E EPS of $5.79 × 16.5x = ~$95.5, where the multiple sits below both the staples sector and CLX's own historical range to reflect stalled organic growth, $3.98B of debt against thin equity, and the CEO transition. Cross-checks bracket the same zone: ~1.7x forward P/S (vs. 2.25x 5-year average) on ~$7.63B FY27E revenue implies ~$107, while a normalized ~5.5% FCF yield on ~$600M of recovered free cash flow implies ~$90 — blending toward the mid-$90s, modestly below the ~$96.57 recent analyst average and well above the current $87.76.